SYNC (SYNC) News
Follow SYNC (SYNC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Saba Capital Holds 16.4% Voting Rights In Syncona As Of Sept 21
Syncona Ltd LSE:SYNC
NEWS | Sep 23, 2026, 08:38 AM UTC
M
Syncona shares rise after Beacon Therapeutics reports positive trial data
Syncona gained 5.8% in European morning trading Monday after portfolio company Beacon Therapeutics said a gene therapy for a blindness-causing disease achieved positive results in a pivotal study.
EQUITY | Sep 21, 2026, 09:52 AM UTC
M
Sycona shares rise on positive gene therapy trial results
Beacon Therapeutics, a Syncona portfolio company, is developing laru-zova for XLRP (inherited retinal disease). The stock jumped after positive drug trial results were reported.
EQUITY | Sep 21, 2026, 08:00 AM UTC
M
Syncona Says Beacon Therapeutics Reports Positive Topline in Vista Trial
Syncona said Beacon Therapeutics delivered a positive topline result in its Phase II/III Vista trial.
EQUITY | Sep 21, 2026, 06:28 AM UTC